Piper Sandler Downgrades Aptiv to Neutral

Piper Sandler analyst Alexander Potter downgrades Aptiv (NYSE:APTV) from Overweight to Neutral.

byBenzinga Newsdesk

November 8, 2021

1 minute read

Piper Sandler analyst Alexander Potter downgrades Aptiv (NYSE:APTV) from Overweight to Neutral.

Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $41

By Benzinga Newsdesk

Today, 5:50 AM

Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $40 to $41.

TVTX

Analysis: Why Did 6 Colleges Shut Down Over The Past 12 Months?

By Phil Hall

Today, 5:50 AM

On March 23, the students and faculty of New Jersey’s Bloomfield College received a letter from the school’s president, Marcheta P. Evans, addressing concerns that the financially struggling college might be forced to close its doors.

SPY

Allscripts Healthcare Solutions’ Business Unit Veradigm Partners With CareMetx; Terms Not Disclosed

By Benzinga Newsdesk

Today, 5:50 AM

Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ:MDRX), and CareMetx, a leading technology-enabled hub services company focused

MDRX

Analyst Ratings

Expert Ratings For Regenxbio

By Benzinga Insights

Today, 5:50 AM

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

RGNX

Piper Sandler Downgrades Aptiv to Neutral

Related Posts

Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $41

Analysis: Why Did 6 Colleges Shut Down Over The Past 12 Months?

Allscripts Healthcare Solutions’ Business Unit Veradigm Partners With CareMetx; Terms Not Disclosed

Expert Ratings For Regenxbio